Bank of America Securities analyst Tazeen Ahmad has reiterated their bearish stance on SAGE stock, giving a Sell rating on October 4. Tazeen ...

Needham analyst Ami Fadia has reiterated their neutral stance on SAGE stock, giving a Hold rating today. Ami Fadia has given his Hold rating ...

Sage Therapeutics has said it will stop the development of dalzanemdor in Alzheimer's disease, a few months after pulling the ...

The biopharmaceutical company isn’t planning further clinical development of dalzanemdor to treat Alzheimer’s.

After a series of setbacks for dalzanemdor, some analysts now expect that Sage won’t reach profitability for awhile — and only if its cost structure undergoes significant changes.

Biogen's stock has had a rough time over the past few months. In late July, not only did European regulators reject Biogen's treatment for Alzheimer's disease, the company and partner Sage ...

Here are the five things you need to know in local business news to start your busy Wednesday, including Amazon's empty office building, Jack's Abby's new buy, shopping plaza sales and what you need ...

Scholar Rock yesterday reported that its experimental treatment for spinal muscular atrophy succeeded in a Phase 3 trial, ...

A new RNAi biotech is breaking ground with $135 million and John Maraganore, Ph.D., holding the key to the city. | A new RNAi ...

The FDA approved Zurzuvae as the first oral therapy for post-partum depression (PPD) in August 2023, although, the agency ...

Imaging in neurosurgery patients showed how the brain's glymphatic system clears waste. ( PNAS) Investigational apitegromab ...